Claims
- 1. A method for the reduction of the viral infectiousness of potentially infectious material, from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses, comprising the steps of:
- treating said potentially infectious material with a hydrophobic phase that is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, and
- separating said hydrophobic phase from the potentially infectious material thus treated.
- 2. The method according to claim 1, wherein said potentially infectious material is human or animal body fluids or fractions derived therefrom.
- 3. The method according to claim 1, wherein said potentially infectious material is blood or blood plasma or processed blood or blood plasma.
- 4. The method according to claim 3, wherein said potentially infectious material is a cryoprecipitate.
- 5. The method according to claim 1, wherein said biologically active substances which can be isolated from said potentially infectious material are proteins.
- 6. The method according to claim 5, wherein said proteins are factors of the blood-clotting cascade.
- 7. The method according to claim 1, wherein said hydrophobic phase consists of non-polar organic liquids.
- 8. The method according to claim 7, wherein said non-polar organic liquids are oils or fats.
- 9. The method according to claim 1, wherein said potentially infectious material is further treated with non-ionic detergents and alkyl phosphates, or polyethers, simultaneously with or subsequent to said hydrophobic phase treatment for enhancing the effectivity of the reduction of infectiousness, thereof.
- 10. The method according to claim 9, wherein said alkyl phosphates comprise tri-n-butyl phosphate.
- 11. The method according to claim 9, wherein said polyethers comprise TRITON derivatives.
- 12. The method according to claim 1, wherein said hydrophobic phase is intimately mixed with said potentially infectious material, and the respective phases are separated following phase separation.
- 13. The method according to claim 1, wherein said material treated with said hydrophobic phase and reduced in infectiousness is further separated into fractions by a separation procedure.
- 14. The method according to claim 13, wherein said separation procedure is affinity chromatography, ion-exchange chromatography, electrophoresis, gel-permeation chromatography, or hydrophobic reverse phase chromatography.
- 15. The method according to claim 1 for the recovery of virus-inactivated biologically active substances.
- 16. The method according to claim 15, wherein said biologically active substances are factors of the blood-clotting cascade.
Priority Claims (1)
Number |
Date |
Country |
Kind |
95 107 710 |
May 1995 |
EPX |
|
Parent Case Info
This application is a nation stage filing of PCT/EP96/01488, filed Apr. 4, 1996, which claims priority of EPO 95 107 710.6, filed May 20, 1995.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP96/01488 |
4/4/1996 |
|
|
2/19/1998 |
2/19/1998 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/36369 |
11/21/1996 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4789545 |
Woods et al. |
Dec 1988 |
|
5648472 |
Gehringer et al. |
Jul 1997 |
|